BCL2 and diffuse large B-cell lymphoma: Double‐expression MYC/BCL2 is known for its adverse prognostic impact, but also BCL2 expression (40%–60% of DLBCL NOS), independently of IPI score or MYC expression (Petrella, Ann Oncol 2017).13